


BMS-1001 free base

ALTERNATE NAME: BMS1001

(2-((3-Cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-5-(2-((3-Cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl)oxy)-5-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-((3-(2,3-dihydrobenzo[b][1,4]dioxin-

methylbenzyl)-D-serine

CATALOG #: B2758-1 1 mg B2758-5 5 mg



MOLECULAR FORMULA: $C_{35}H_{34}N_2O_7$

MOLECULAR WEIGHT: 594.66

CAS NUMBER: 2113650-03-4

APPEARANCE: Crystalline solid

PURITY: ≥98%

SOLUBILITY: DMSO

DESCRIPTION: BMS-1001 is a potent inhibitor of the interaction between programmed death protein 1 (PD-1) and its

ligand programmed cell death ligand 1 (PD-L1) (IC50 = 2.25 nM). BMS-1001 is capable of alleviating

the PD-1/PD-L1 immune checkpoint-mediated exhaustion of Jurkat T-lymphocytes

STORAGE TEMPERATURE: -20°C. Protect from light

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of

exposure.

RELATED PRODUCTS:

BioSim™ anti-Pembrolizumab (Keytruda®) (Human) ELISA Kit (E4397) BioSim™ Pembrolizumab (Keytruda®)(Human) ELISA Kit (E4383)

PD-1/PD-L1 Inhibitor 2 (B1050) PD-1/PD-L1 Inhibitor 1 (B1213)

DISCLAIMER: FOR RESEARCH USE ONLY! Not to be used on humans.